VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Tuesday. The brokerage set a “sell” rating on the stock.

A number of other research analysts have also recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research note on Thursday, February 6th. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Price Performance

Shares of VNRX opened at $0.62 on Tuesday. The firm has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.65. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.10. The stock has a market cap of $57.27 million, a price-to-earnings ratio of -1.72 and a beta of 1.20.

Insider Buying and Selling

In related news, Director Guy Archibald Innes purchased 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the acquisition, the director now directly owns 617,085 shares in the company, valued at $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Cameron John Reynolds purchased 139,811 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 358,266 shares of company stock worth $204,212. 12.80% of the stock is owned by insiders.

Hedge Funds Weigh In On VolitionRx

Hedge funds have recently made changes to their positions in the stock. Two Sigma Securities LLC acquired a new position in shares of VolitionRx in the 4th quarter valued at $29,000. Millennium Management LLC acquired a new position in shares of VolitionRx during the 4th quarter valued at $36,000. Northern Trust Corp lifted its holdings in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. lifted its holdings in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.